PharmaCyte Biotech, Inc.: Form 10-Q for the period ended Oct 31, 2013
Filed with the SEC on Dec 16, 2013 and accepted by EDGAR at Dec 16, 2013, 06:04 ET.
Management's discussion and analysis
As filed, 6,640 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
This following information specifies certain forward-looking statements of our management. Forward-looking statements are statements that estimate the happening of future events and are not based on historical fact. Forward-looking statements may be identified by the use of forward-looking terminology, such as “may”, “shall”, “could”, “expect”, “estimate”, “anticipate”, “predict”, “probable”, “possible”, “should”, “continue”, or similar terms, variations of those terms or the negative of those terms. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information we have when those statements are made or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. The forward-looking statements specified in the following information have been compiled by our management on the basis of assumptions made by management and considered by management to be reasonable. Our future operating results, however, are impossible to predict, and no representation, guaranty, or warranty is to be inferred from those forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements.
Forward-looking statements include, but are not limited to, the following:
- Statements relating to our future business and financial performance;
- Statements relating to future clinical trials and regulatory approvals of our products;
- Statements relating to our competitive position; and
- Other material future developments that you may take into consideration.
Results of Operations for the Three Months Ended October 31, 2013 and 2012
There was no revenue generated during the three months ended October 31, 2013. Revenues decreased from $6,287 to $0 from the three months ended October 31, 2012 compared to the same period in 2013 as a result of multiple factors. In 2012, we made a decision to discontinue the sale of Cinnergen because the cost of manufacturing and marketing Cinnergen was in excess of the revenues generated. The prior year's revenue was derived solely from the sale of Cinnergen, which sales occurred even in the absence of substantial marketing efforts. We instead utilized available funds to acquire the necessary components and personnel for our biotechnology operations to move forward in accordance with our strategy and plans discussed in Note 2 above.
Selling, General and Administrative Expenses
General and administrative expenses during the three months ended October 31, 2013 compared to the three months ended October 31, 2012, increased by $97,648 to $165,280 as compared to $67,632 in the prior period. The increase can be contributed to an overall increase in spending on marketing, investor relations and other consulting services.
For the three months ended October 31, 2013, compensation expense decreased by $24,562 to $140,134 as compared to $164,696 for the same period in the prior year. The decrease is a result of fewer shares of Common Stock being issued during the period.
During the three months ended October 31, 2013, net loss increased by $5,275,254 to $5,658,070, as compared to $382,816 in the prior period. The increase in net loss over the prior period is almost entirely attributed to a $5,255,000 loss on the conversion of 5,000 shares of ‘Series E Preferred Stock to 15,000,000 shares of Common Stock.
Results of Operations for the Six Months Ended October 31, 2013 and 2012
There was no revenue generated during the six months ended October 31, 2013. Revenues decreased from $12,913 to $0 during the six months ended October 31, 2012 as compared to the same period in 2013. In 2012, we made a decision to discontinue the sale of Cinnergen because the cost of manufacturing and marketing Cinnergen was in excess of the revenues generated. The prior year's revenue was derived solely from the sale of Cinnergen, which sales occurred even in the absence of substantial marketing efforts. We instead utilized available funds to acquire the necessary components and personnel for our biotechnology operations to move forward in accordance with our strategy and plans discussed in Note 2 above.
Selling, General and Administrative Expenses
General and administrative expenses during the six months ended October 31, 2013, compared to the six months ended October 31, 2012, decreased by $13,152 to $284,486 as compared to $297,638 in the prior period. The decrease can be contributed to more spending on marketing, investor relations and other consulting services in the first three months of the current fiscal year.
For the six months ended October 31, 2013, compensation expense increased by $516,384 to $862,261 as compared to $345,877 for the same period in the prior year. The increase is a result of a combination of an overall increase in the share price of our Common Stock as well as additional shares being issued for compensation. In addition, during the six months ended October 31, 2013, the Company issued Common Stock to directors of the Company valued at $480,000.
During the six months ended October 31, 2013, net loss increased by $9,431,104 to $10,324,437 as compared to $893,333 in the prior period. The increase in net loss over the prior period is attributed to the increase in the loss from operations of $961,679 combined with a loss on settlement of debt of $3,973,795 and a loss on the conversion of 8,500 shares of Series E Preferred Stock to 54,000,000 shares of Common Stock in the amount of $5,895,000.
Liquidity and Capital Resources
By adjusting the Company’s operations and by utilizing the $1,136,000 in proceeds from the sale of 39,622,400 shares of Common Stock to various investors through the Company’s Private Placement Memorandum and an additional $3,060,000 from the sale of 23,000,000 shares of Common Stock to other accredited investors, we have been able to maintain sufficient capital resources to meet projected cash flow needs of the Company. Failure by the Company to generate sufficient liquidity from operations or in raising sufficient capital resources on acceptable terms may have a materially adverse effect on our businesses, results of operations, liquidity and financial condition. We have no off-balance sheet arrangements, special purpose entities, financing partnerships or guarantees.
Market risk
As filed, 568 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
In addition to the other information set forth in this Report, you should carefully consider the factors discussed in Part I, Item 1A., “Risk Factors” in our Annual Report on Form 10-K, as amended by our Report on Form 10-K/A for the year ended April 30, 2013. These could materially affect our businesses, financial position and results of operations. There are no material changes from the risk factors set forth in Part I, Item 1A, “Risk Factors,” of our Annual Report on Form 10-K, as amended by our Report on Form 10-K/A, for the fiscal year ended April 30, 2013.
Controls and procedures
As filed, 1,242 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in the Securities Exchange Act of 1934, as amended (“Exchange Act”) Rules 13a-15(e) and 15d-15(e)). Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of the end of the period covered in this Report, our disclosure controls and procedures were effective to ensure that information required to be disclosed in reports filed under the Exchange Act is recorded, processed, summarized and reported within the required time periods and is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.
There have been no changes to our internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) that occurred during the fiscal quarter ended October 31, 2013 which have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Risk factors
As filed, 598 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
In addition to the other information set forth in this Report, you should carefully consider the factors discussed in Part I, Item 1A., “Risk Factors” in our Annual Report on Form 10-K, as amended by our Annual Report on Form 10-K/A, for the fiscal year ended April 30, 2013. The information set forth in these Reports could materially affect the Company’s business, financial position and results of operations. There are no material changes from the risk factors set forth in Part I, Item 1A, “Risk Factors,” of our Annual Report on Forms 10-K and 10-K/A for the fiscal year ended April 30, 2013.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2013-10-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2013-08-01 to 2013-10-31 | $0 | us-gaap:Revenues |
| Revenue | 6 months2013-05-01 to 2013-10-31 | $0 | us-gaap:Revenues |
| Cost of revenue | 3 months2013-08-01 to 2013-10-31 | $0 | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2013-05-01 to 2013-10-31 | $0 | us-gaap:CostOfRevenue |
| Gross profit | 3 months2013-08-01 to 2013-10-31 | $0 | us-gaap:GrossProfit |
| Gross profit | 6 months2013-05-01 to 2013-10-31 | $0 | us-gaap:GrossProfit |
| Operating income | 3 months2013-08-01 to 2013-10-31 | −$448.6k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2013-05-01 to 2013-10-31 | −$1.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2013-08-01 to 2013-10-31 | $3.6k | us-gaap:InterestExpense |
| Interest expense | 6 months2013-05-01 to 2013-10-31 | $14.0k | us-gaap:InterestExpense |
| Net income | 3 months2013-08-01 to 2013-10-31 | −$5.7m | us-gaap:NetIncomeLoss |
| Net income | 6 months2013-05-01 to 2013-10-31 | −$10.3m | us-gaap:NetIncomeLoss |
| Basic EPS | 3 months2013-08-01 to 2013-10-31 | −$0.01 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2013-05-01 to 2013-10-31 | −$0.02 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 6 months2013-05-01 to 2013-10-31 | −$366.8k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Current assets | At period end2013-10-31 | $472.6k | us-gaap:AssetsCurrent |
| Total assets | At period end2013-10-31 | $4.6m | us-gaap:Assets |
| Current liabilities | At period end2013-10-31 | $991.0k | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2013-10-31 | $991.0k | us-gaap:Liabilities |
| Shareholders' equity | At period end2013-10-31 | $3.6m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001019687-13-004824. Last ingested by Listed: Nov 14, 2026, 20:52 ET. Listed shows no prices and gives no investment advice.